0001169245-22-000007.txt : 20220228 0001169245-22-000007.hdr.sgml : 20220228 20220228191910 ACCESSION NUMBER: 0001169245-22-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220224 FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hanson Kristopher CENTRAL INDEX KEY: 0001789970 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38697 FILM NUMBER: 22692910 MAIL ADDRESS: STREET 1: C/O PHASEBIO PHARMACEUTICALS, INC. STREET 2: 1 GREAT VALLEY PKWY., SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc CENTRAL INDEX KEY: 0001169245 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030375697 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 981-6500 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Phase Biosciences Inc DATE OF NAME CHANGE: 20061013 FORMER COMPANY: FORMER CONFORMED NAME: DT BIOSCIENCES INC DATE OF NAME CHANGE: 20020315 4 1 wf-form4_164609392829155.xml FORM 4 X0306 4 2022-02-24 0 0001169245 PhaseBio Pharmaceuticals Inc PHAS 0001789970 Hanson Kristopher C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30 MALVERN PA 19355 0 1 0 0 VP, Head of Legal Restricted Stock Unit 2022-02-24 4 A 0 18750 0 A Common Stock 18750.0 18750 D Employee Stock Option (right to buy) 1.13 2022-02-24 4 A 0 87500 0 A 2032-02-24 Common Stock 87500.0 87500 D Each Restricted Stock Unit is the economic equivalent of one share of PhaseBio Pharmaceuticals, Inc. common stock and is converted into common stock upon vesting subject to the reporting person's continued service through each such date. These Restricted Stock Units vest in equal one-third amounts on April 1, 2023, 2024, and 2025. The shares subject to the option shall vest in equal monthly installments over 48 months from February 24, 2022, subject to the reporting person's continued service through each such date. /s/ John P. Sharp, Attorney-in-fact 2022-02-28